Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that removing PPARγ specifically from mouse adipose tissue led to severe fat loss, insulin resistance, diabetes, and associated metabolic abnormalities.

This study found that maternal PPARγ is essential for preventing the production of inflammatory lipids in mouse milk, which can otherwise cause inflammation, alopecia, and growth retardation in nursing pups.

This review discusses the essential roles and complex regulation of PP2A in various physiological processes and reports no clinical results; the authors highlight the need for further mouse model research to explore PP2A's therapeutic potential.

This review discusses the role of PPARs in skin health, suggesting both potential benefits and adverse effects, but reports no new experimental results; the authors emphasize the need for more research to understand these pathways.

This review discusses the role of peroxisome proliferator-activated receptors and their agonists in dermatology but reports no new clinical results.

This study found that PPAR alpha, -delta, and -gamma are expressed in human hair follicle cells, and clofibrate exhibited a beneficial effect on hair follicle survival in culture within a specific concentration range.

This study suggests PPAR isotypes play distinct roles in skin, influencing epidermal barrier formation, sebocyte differentiation, and lipid production, with potential implications for treating skin disorders.

This review discusses the role of PPAR-γ in the pathogenesis of primary cicatricial alopecia, including its involvement in lichen planopilaris and treatment trials using PPAR-agonists, and reports no new clinical results.

This study found that the selective PPARγ modulator GMG-43AC may inhibit unwanted hair growth by inducing catagen phase while preserving hair follicle epithelial progenitor cells, suggesting potential in anti-hirsutism therapy.

This review synthesizes current research on PPAR-γ signaling in hair follicle biology and its potential role in treating hair growth disorders like scarring alopecia and hirsutism, but reports no new clinical results.

This study found that topical application of cyclosporin A and FK506 induces new hair growth in mice, while ascomycin and rapamycin do not, suggesting hair induction is not due to immunosuppression.

This study showed that knocking out the Ppp2ca gene in the epidermis of mice led to significant hair loss and disrupted hair follicle morphogenesis and regeneration.

This study found that the PP2A-B55α regulatory subunit is crucial for ectodermal development in mice, with knockout embryos displaying severe neural and epidermal defects and failing to survive to birth.

This study found that the absence of vitamin D receptor-mediated suppression of PPARγ expression causes hair loss in VDR-null mice.

This study found that loss of epidermal PPARγ in mice altered the expression of many genes related to skin inflammation, keratinization, and sebaceous gland function, indicating its key role in maintaining skin homeostasis.

This study found that the retinoid receptor and PPAR pathway are involved in hair follicle miniaturization in androgenetic alopecia, alongside androgen receptors.

In this study, aleglitazar and its metabolite M6 were evaluated for safety in non-clinical settings, revealing organ-targeting effects common to PPAR agonists but no significant tumor increase in rat carcinogenicity studies, supporting progression to Phase 3 clinical trials.

This study found that PPARα agonists provided protective effects in mouse models of alopecia areata by promoting early reversal of the condition and inhibiting T effector cell function, indicating potential therapeutic value for this inflammatory condition.

This study found that hepatic KRT79 expression is regulated by PPARA and is significantly associated with liver stress, suggesting it may serve as a diagnostic marker for liver diseases.

This study found that astilbin downregulates effector CD4+ T cell activities through the CYP1B1/ROS/PPARγ pathway, suggesting its potential use in treating inflammation.

This study found that FAM19A5 acts as a negative regulator of wound healing by hindering keratinocyte migration and partially transitioning them between epithelial and mesenchymal states, suggesting that targeting the FAM19A5-PPARD-Snail axis could offer new therapeutic options for impaired wound repair.

This source explains that Equine Cushing’s disease, or PPID, in horses is due to the degeneration of brain cells producing dopamine, leading to elevated cortisol levels and characteristic symptoms; it outlines diagnosis methods and emphasizes life-long pergolide treatment to manage the condition.

In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.

The researchers reported that PPARβ/δ may influence the yak hair follicle cycle by modulating lipid metabolism in dermal papilla cells, with varying expression during different hair growth phases, affecting both lipid content and cell proliferation.

In this study, researchers performed the first integrated transcriptomic and proteomic analysis of scalp biopsies from male androgenetic alopecia patients, finding a significant association between PPAR signaling pathways and AGA, with ME1 identified as a key regulator in this process.

In this study, human cell models of hair follicles showed that araliadiol, a plant-derived polyacetylene compound, promotes hair growth through the p38/PPAR-γ signaling pathway, suggesting its potential as a new drug candidate for alopecia treatment.

This study found that neonatal Regulatory T cells are crucial for maintaining PPARγ signaling in hair follicles, which supports melanocyte stem cell function and skin pigmentation during early postnatal development.

A specific RNA molecule blocks hair growth by affecting a protein related to hair loss conditions.

This study found that individuals with homozygous loss-of-function mutations in PLAAT3 experience a novel type of partial lipodystrophy linked to defects in white adipose tissue differentiation and function.

This study found that the PPARγ modulator NAC-GED-0507-Levo may protect hair follicles from chemotherapy-induced damage, potentially offering a strategy to address irreversible hair loss in cancer patients.